Odey Asset Management Group Ltd purchased a new position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 20,277 shares of the biopharmaceutical company’s stock, valued at approximately $2,467,000.

Several other large investors have also modified their holdings of ALXN. Guardian Life Insurance Co. of America raised its stake in shares of Alexion Pharmaceuticals by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Eqis Capital Management Inc. lifted its holdings in Alexion Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock valued at $824,000 after buying an additional 38 shares during the period. Rathbone Brothers plc lifted its holdings in Alexion Pharmaceuticals by 2.5% in the second quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 50 shares during the period. Cleararc Capital Inc. lifted its holdings in Alexion Pharmaceuticals by 1.0% in the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock valued at $666,000 after buying an additional 53 shares during the period. Finally, Seven Bridges Advisors LLC lifted its holdings in Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 53 shares during the period. Institutional investors own 94.25% of the company’s stock.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The disclosure for this sale can be found here. Insiders have sold 17,070 shares of company stock worth $2,416,869 over the last ninety days. 4.35% of the stock is owned by insiders.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 1.26% during trading on Monday, reaching $142.06. The company’s stock had a trading volume of 608,177 shares. The stock has a market cap of $31.71 billion, a PE ratio of 61.60 and a beta of 1.39. The company’s 50-day moving average is $139.14 and its 200-day moving average is $124.77. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.13 earnings per share. Equities analysts expect that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “20,277 Shares in Alexion Pharmaceuticals, Inc. (ALXN) Acquired by Odey Asset Management Group Ltd” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/02/20277-shares-in-alexion-pharmaceuticals-inc-alxn-acquired-by-odey-asset-management-group-ltd.html.

A number of equities analysts have issued reports on the stock. Jefferies Group LLC set a $120.00 price objective on shares of Alexion Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, June 8th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $142.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, June 9th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th. Morgan Stanley reissued an “overweight” rating and issued a $138.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, June 14th. Finally, UBS AG reissued a “buy” rating and issued a $108.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, June 14th. Six research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $157.21.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.